Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management

NCT05362760 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Hormone Receptor-positive Metastatic Breast Cancer
HER2-negative Metastatic Breast Cancer

Interventions

DRUG: Abemaciclib + Aromatase Inhibitor
DRUG: Abemaciclib + Fulvestrant

Sponsor

Prof. Wolfgang Janni

Collaborators

[object Object]